INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 06, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 500 | $16.01 | 4,027 |
| Feb 06, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 200 | $16.02 | 3,827 |
| Feb 06, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 500 | $16.21 | 3,327 |
| Feb 06, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $16.22 | 3,227 |
| Feb 06, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $16.23 | 3,127 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 16,000 | $7.41 | 19,127 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Open market or private sale of non-derivative or derivative security | 16,000 | $15.86 | 3,127 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,000 | $7.41 | 27,127 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,843 | $16.40 | 16,284 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,558 | $16.40 | 11,726 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.